Oral semaglutide shows significant promise in improving diabetes control and cardiovascular health, study reveals

FHS
May 30, 2024
1:05 am

A recent study in the Journal of Clinical Medicine found that oral semaglutide significantly improves glycemic control and reduces body weight in type 2 diabetes patients after 24 weeks of treatment.

Why is health care cybersecurity so bad?

Year after year, more Americans are affected by health care data breaches. Though health savings accounts, pharmacies, and major hospitals have all been attacked in

December 4, 2024

Study finds among outpatients with mild to moderate COVID-19, treatment with fluvoxamine does not reduce duration of symptoms

Researchers investigate the effects of high-dose fluvoxamine among patients with mild-to-moderate COVID-19.

November 22, 2023

Study delves into the lives of neurodivergent psychiatrists

Groundbreaking research exploring the experiences of autistic psychiatrists has revealed that psychiatrists who are unaware that they themselves are autistic may fail to recognise the

November 1, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.